Seaport Therapeutics

Seaport Therapeutics’ stable 6.1 M‑share holding by GAP Coinvestments confirms investor confidence, while PureTech Health’s recent purchase highlights growing interest in its neuropsychiatric platform—key insights for biotech portfolio managers seek…

PureTech Health’s 5% buy‑back of Seaport Therapeutics signals confidence and a potential IPO move, boosting insider value in this neuro‑psychiatric biotech.